

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Carfilzomib in combination with lenalidomide and dexamethasone  
for previously treated multiple myeloma**

**Batch 40**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During the scoping workshop one attendee noted that multiple myeloma is particularly prevalent in people of African and Caribbean family origin. The attendee felt that a 'no' recommendation in final guidance would disproportionately impact on this group.
--

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The increased prevalence of multiple myeloma in people of African and Caribbean family origin is a feature of the disease, rather than an equalities issue relating to this technology. Therefore this issue is outside the remit of NICE technology appraisals guidance.
---

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No changes were made to the scope to highlight potential equality issues
--

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders relating to potential equality issues have been identified during the scoping process/

**Approved by Associate Director (name):** ...Melinda Goodall.....

**Date:** 19/10/2015